As in patients with AML treated with FLT3 inhibitors, the emergence of RAS pathway mutated clones in ruxolitinib-treated patients could be due to a specific resistance induced by the upregulation of RAS signaling 3. Here, FLT3 is linked to acute myeloid leukemia.